NCT04125082 - A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2019

Primary Completion Date

March 15, 2020

Study Completion Date

March 15, 2020

Conditions

Type 2 Diabetes Treated With Insulin

Interventions

DRUG

Afrezza Inhalant Product

Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.

Trial Locations (1)

78229

Diabetes and Glandular Disease Clinic, P.A., San Antonio